ÌÇÐÄvlog´«Ã½

Inflammatory Bowel Disease Diagnostic Market Analysis

The Global Inflammatory Bowel Disease Diagnostic Market size is estimated at USD 3.88 billion in 2024, and is expected to reach USD 4.67 billion by 2029, growing at a CAGR of 3.78% during the forecast period (2024-2029).

The COVID pandemic and statewide lockdown have had a major impact on patients with inflammatory bowel disease (IBD), including delayed diagnosis and problems getting healthcare. According to the study titled "Reduction in Inflammatory Bowel Disease Healthcare During the Coronavirus Disease 2019 Pandemic: A Nationwide Retrospective Cohort Study" published in the Gastroenterology in February 2021, IBD diagnoses dropped by 6.5% during the COVID-19 pandemic, with a maximum drop of 46.3%. The number of additional infection-related complications has increased along with COVID-19 prevalence. A report by the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, indicated that among patients with IBD, adverse COVID-19 outcomes were related to age and other co-morbidities. Thus, the decline in the IBD diagnosis during COVID-19 significantly hampered the market growth.

The market is driven by the rise in the prevalence of IBD, the growing need for early diagnosis of IBD, and product launches by the key market players. According to a report by the Centers for Disease Control and Prevention (CDC) published in April 2021, on World IBD Day (May 19), about 7 million around the world suffer from IBD. The report also stated that the rate of prevalence of the disease has significantly increased during the last two decades. Thus, the growing prevalence of the IBD is anticipated to drive the demand for its diagnosis thereby boosting the market. Additionally, according to the study titled "Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study" by Aderson O.M.C. Damiao, published in June 2022, in Brazil, the prevalence of ulcerative colitis and crohn's disease rose from 30.0 per 100,000 in 2012 to 100.1 per 100,000 in 2020 and 15.7 to 56.5 per 100,000 in 2012 to 12.6 to 33.7 per 100,000 in 2020 respectively. Thus, the growing prevalence of IBD diseases such as crohn's disease and ulcerative colitis is anticipated to drive the demand for its diagnosis thereby boosting segment growth.

Additionally, the market growth is supported by several strategies used by the major market players, including product launches, mergers, and acquisitions. For instance, in November 2021, Medtronic plc received the United States Food and Drug Administration (FDA) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures.

The market is anticipated to grow as a result of the rising demand for IBD diagnoses. However, it is anticipated that the lack of public awareness and strict regulations for entry may impede the market's expansion.

Inflammatory Bowel Disease Diagnostic Market Trends

Endoscopy Segment is Expected to Account for the Highest Market Share

Inflammatory Bowel Disease Diagnostic Industry Segmentation

As per the scope of this report, inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract. The two classifications of IBD are Crohn's disease and ulcerative colitis. Prolonged inflammation can cause damage to the GI tract. The inflammatory Bowel Disease (IBD) Diagnostic Market is segmented by Diagnostics (Blood Tests, Fecal Tests, Endoscopy, Biopsy and Others), Disease Type (Ulcerative Colitis, Crohn's Disease), End User (Hospitals, Diagnostic Laboratories, Others End User), Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers values (in USD) for the above segments.